title: Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
authors.forename: Cinzia
authors.initials: C
authors.lastname: Pellegrini
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Maglie
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
authors.forename: Lisa
authors.initials: L
authors.lastname: Argnani
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy. pierluigi.zinzani@unibo.it.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
mesh_terms: D064591:Allografts; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage; D000079963:Brentuximab Vedotin; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy / Q000628:therapy; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects; D000077269:Lenalidomide; D008081:Liposomes; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D014182:Transplantation, Autologous; D055815:Young Adult
chemical_list: D000903:Antibiotics, Antineoplastic; D018796:Immunoconjugates; D008081:Liposomes; C506643:liposomal doxorubicin; D003561:Cytarabine; D011092:Polyethylene Glycols; D013792:Thalidomide; D005047:Etoposide; D000079963:Brentuximab Vedotin; D004317:Doxorubicin; D000069461:Bendamustine Hydrochloride; D000077269:Lenalidomide; D008558:Melphalan; D002330:Carmustine
keywords: Hodgkin's lymphoma; allogeneic transplantation; multi-relapsed; pegylated liposomal doxorubicin; response